Vesicle composition, method for producing the same, and cosmetic base containing the same

Abstract

Provided are a vesicle composition having improved storage stability, a method for producing the same, and a cosmetic base containing the vesicle composition. A vesicle composition includes: water; and vesicles made of a two-chain anionic surfactant and a two-chain cationic surfactant.

Description

Technical Field

[0001] This invention relates to vesicle compositions and methods for manufacturing the same, as well as cosmetic bases containing vesicle compositions. Background Technology

[0002] Amphiphilic compounds, possessing both hydrophilic and hydrophobic properties, include, for example, phospholipids, which form spherical vesicles in an aqueous phase consisting of a bilayer-like membrane. These bilayer vesicles are called liposomes or vesicles, and they can retain aqueous components within their interior and / or oily components within their membrane. Therefore, for example, due to their ability to retain pharmaceutical agents for long-term efficacy during administration, such vesicles are used as microcapsules in pharmaceuticals, cosmetics, and food. By forming liposomes or vesicles, compositions with excellent appearance, such as transparency, can be obtained, and therefore, such vesicles are also expected to be used as cosmetic bases.

[0003] To date, a great deal of research has been conducted on vesicles.

[0004] For example, Patent Document 1 discloses vesicles containing 1), 2) and 3), where 1) is α,ε-bis(γ-N-(carbon number 10-30)acylglutamyl)lysine and / or its salt, 2) is ceramide and / or its derivative, and 3) is one or more selected from glycerol fatty acid esters, polyglycerol fatty acid esters and pyroglutamic acid glycerol fatty acid esters.

[0005] Furthermore, Patent Document 2 discloses a vesicle composition characterized by containing the following components (a) to (e): (a) sodium bis(lauramide-glutamine)lysine (b) cholesterol and / or phytosterols (c) monostearate glyceryl ether (d) dipropylene glycol (e) water.

[0006] Furthermore, Patent Document 3 discloses the formation of vesicles in a liquid by mixing cationic and anionic surfactant molecules. Additionally, the cationic and anionic surfactant molecules used here are single-chain.

[0007] Furthermore, Patent Document 4 discloses the formation of vesicles by mixing a two-chain cationic surfactant with an anionic surfactant. Additionally, the anionic surfactant used here is a single-chain surfactant.

[0008] Existing technical documents

[0009] Patent documents

[0010] Patent Document 1: International Publication No. 2008 / 149601

[0011] Patent Document 2: Japanese Patent Application Publication No. 2008-255109

[0012] Patent Document 3: Japanese Patent Application Publication No. 2008-056513

[0013] Patent Document 4: Japanese Patent Application Publication No. 2006-327849 Summary of the Invention

[0014] The problem that the invention aims to solve

[0015] However, conventional vesicles using surfactants have been known to have insufficient shelf-life stability. In particular, when using vesicles in cosmetic bases, there is a desire to improve shelf-life stability and usability.

[0016] Therefore, the present invention is made to solve the above-mentioned problems, and its object is to provide a stable vesicle composition and a method for manufacturing the same, as well as a cosmetic base containing the stable vesicle composition.

[0017] Methods for solving problems

[0018] The inventors have discovered that the above-mentioned problems can be solved by the following means.

[0019] Option 1

[0020] A vesicle composition comprising:

[0021] Water; and

[0022] Vesicles made from bichain anionic surfactants and bichain cationic surfactants.

[0023] Option 2

[0024] According to the vesicle composition of Scheme 1, the average particle size of the vesicles is less than 150 nm.

[0025] Option 3

[0026] According to the vesicle composition of Scheme 1 or 2, the vesicles retain an oily component.

[0027] Option 4

[0028] According to any one of the vesicle compositions in Schemes 1 to 3, the molar ratio of the above-mentioned bichain anionic surfactant to the above-mentioned bichain cationic surfactant is 8:2 to 5:5.

[0029] Option 5

[0030] According to any one of the vesicle compositions of Schemes 1 to 4, the above-mentioned bichain anionic surfactant has two alkyl or acyl groups having 8 to 20 carbon atoms.

[0031] <Option 6>

[0032] According to any one of the vesicle compositions of Schemes 1 to 5, the above-mentioned dichain cationic surfactant has two alkyl or acyl groups having 8 to 20 carbon atoms.

[0033] <Option 7>

[0034] According to any one of the vesicle compositions in Schemes 1 to 6, the above-mentioned bichain anionic surfactant is sodium di(lauramide-glutamine)lysine.

[0035] <Option 8>

[0036] According to any one of the vesicle compositions in Schemes 1 to 7, the above-mentioned two-chain cationic surfactant is distearate dimethylammonium chloride.

[0037] <Option 9>

[0038] A cosmetic base comprising the vesicle composition described in any one of Schemes 1 to 8.

[0039] <Option 10>

[0040] A method for manufacturing the vesicle composition according to any one of claims 1 to 8, comprising: mixing an alcohol solution containing the above-mentioned bichain anionic surfactant and the above-mentioned bichain cationic surfactant with water to form the above-mentioned vesicles.

[0041] <Option 11>

[0042] A method for manufacturing the vesicle composition according to any one of claims 1 to 8, comprising: dissolving the above-mentioned bichain anionic surfactant and the above-mentioned bichain cationic surfactant in water to form the above-mentioned vesicles.

[0043] The effects of the invention

[0044] According to the present invention, a vesicle composition with improved storage stability and a method for manufacturing the same, as well as a cosmetic base comprising the vesicle composition, can be provided. Attached Figure Description

[0045] Figure 1 This is a state diagram of the DLGLS-DSAC-water system based on the molar ratio of DSAC (dichain cationic surfactant) to DLGLS (dichain anionic surfactant).

[0046] Figure 2 A graph showing the Cryo-TEM observations of the vesicles obtained in Example 1. Detailed Implementation

[0047] The embodiments of the present invention will now be described in detail. However, the present invention is not limited to the following embodiments and can be implemented in various ways within the scope of the invention's intent.

[0048] Vesicle Composition

[0049] The vesicle composition of the present invention comprises:

[0050] Water; and

[0051] Vesicles formed by bichain anionic surfactants and bichain cationic surfactants.

[0052] The inventors conducted in-depth research and discovered that vesicles are formed by mixing a bichain anionic surfactant and a bichain cationic surfactant in a specific molar ratio. Furthermore, the present invention was completed by using vesicles formed from such bichain anionic surfactant and bichain cationic surfactant.

[0053] <Vapule>

[0054] The vesicles of the present invention can be formed from bichain anionic surfactants and bichain cationic surfactants.

[0055] The average particle size of the vesicles is not particularly limited, and for example, it can be 500 nm or less. By controlling the average particle size of the vesicles, the vesicle composition can be adjusted to be translucent or transparent. Therefore, from the viewpoint of imparting transparency to the vesicle composition, the average particle size of the vesicles of the present invention can be 150 nm or less, 120 nm or less, 100 nm or less, 95 nm or less, 90 nm or less, 85 nm or less, 80 nm or less, 75 nm or less, 70 nm or less, or 60 nm or less. Furthermore, the lower limit of the average particle size of the vesicles is not particularly limited, but can be 20 nm or more, or 50 nm or more. In addition, the average particle size of the vesicles can be measured, for example, using a Zeta Siennano ZS (manufactured by Sysmex Co., Ltd.) using dynamic light scattering method.

[0056] In this invention, the average particle size of vesicles can be controlled by adjusting the molar ratio of a bichain anionic surfactant to a bichain cationic surfactant that can form vesicles.

[0057] The following describes, by way of example, the formation of vesicles when using sodium bis(lauramide-glutamine)lysine (hereinafter also referred to as "DLGLS") as a two-chain anionic surfactant and distearate dimethyl ammonium chloride (hereinafter also referred to as "DSAC") as a two-chain cationic surfactant, based on adjusting the molar ratio of the two surfactants.

[0058] Figure 1 This is a state diagram of the DLGLS-DSAC-water system based on the molar ratio of DSAC (dichain cationic surfactant) to DLGLS (dichain anionic surfactant). Figure 1 As shown, when the molar ratio of DLGLS to DSAC is 0:10, i.e., in the DSAC and water system, the melting point (T1) of DSAC is approximately 34°C. At temperatures below this melting point (T1), the system is in a hydrated crystalline state; at temperatures above the melting point (T1), DSAC dissolves, and the system is in a plate-like crystalline state (represented by "Lα"). The melting point decreases further with increasing the molar ratio of DLGLS. For example, for a DLGLS to DSAC molar ratio of 1:9 to 4:6, the melting point continues to decrease. Furthermore, taking the melting point at each molar ratio as a boundary, at temperatures below the melting point, the system is in a hydrated crystalline state; at temperatures above the melting point, the system is in a hexagonal lattice state (represented by "H2"), a mixed state of plate-like and hydrated crystalline states (represented by "Lα+α-type"), or a plate-like crystalline state ("Lα"). Surprisingly, when the molar ratio of DLGLS to DSAC becomes 5:5, the melting point of DSAC disappears, and vesicles (denoted as "Lα'") form within the system. Furthermore, these vesicles persist within the system up to a certain range in the molar ratio of DLGLS to DSAC, confirming their presence up to approximately 8:2. Beyond 8:2 up to 10:0, the vesicles disappear, and the system becomes a micelle state (denoted as "L1").

[0059] Thus, it has been demonstrated that vesicles can be formed by mixing a binary anionic surfactant with a binary cationic surfactant in a specific molar ratio using the DLGLS-DSAC-water system.

[0060] What is even more surprising is that the average particle size of the vesicles formed in this way can be controlled to be more uniform and smaller than the average particle size of vesicles reported to date.

[0061] Furthermore, since DLGLS and DSAC are highly safe for the skin, the vesicles formed from them are preferred for use as cosmetic bases.

[0062] Furthermore, such as Figure 1As shown, it is evident that without DLGLS, it is difficult to stably disperse DSAC in water near room temperature, and vesicles are difficult to form without applying heat above the melting point. In contrast, the present invention, by mixing DLGLS and DSAC at a specific molar ratio (8:2 to 5:5), enables the formation of stable vesicles near room temperature. From this perspective, the vesicles of the present invention are also stable near room temperature and are suitable for use as a cosmetic base.

[0063] Furthermore, it's possible that the aforementioned PERICEA-DLGLS-water system is merely an example. It's speculated that other bipolar anionic and cationic surfactants, by adjusting their molar ratio to control vesicle formation and average vesicle size, exhibit similar tendencies. However, it's important to understand that the specific molar ratio of DLGLS to DSAC in other vesicle-forming bipolar anionic and cationic surfactant systems may not be identical to that in the DLGLS-DSAC-water system.

[0064] In this invention, the molar ratio of the bichain anionic surfactant to the bichain cationic surfactant (bichain anionic surfactant: bichain cationic surfactant) can be, for example, 8:2 to 5:5, 7.5:2.5 to 5:5, 7:3 to 5:5, or 7:3 to 6:4.

[0065] Furthermore, in order to form the vesicles of the present invention, from the viewpoint of vesicle formation and stability, the total amount of the bichain anionic surfactant and the bichain cationic surfactant mixed relative to the total amount of the composition can be, for example, 0.1% by mass or more, 0.2% by mass or more, or 0.3% by mass or more, or even 10% by mass or less, or 5% by mass or less.

[0066] Furthermore, as described above, in this invention, vesicles can be formed by mixing a bichain anionic surfactant and a bichain cationic surfactant in a specific molar ratio. Therefore, it is not necessary to mix in "forming aids" used in the past to help vesicle formation, or the mixing ratio can be lower than in the past. Therefore, in order to form the vesicles of this invention, when forming aids are mixed, the total mixing amount of the bichain anionic surfactant and the bichain cationic surfactant to the mass ratio of the forming aid can be 1:0.0005 or less.

[0067] Furthermore, in this invention, the confirmation of whether vesicles have formed can be made, for example, by observation using Cryo-TEM.

[0068] (Dual-chain anionic surfactant)

[0069] In this invention, "anionic surfactant" may comprise an agent or compound that exhibits the properties of anionic surfactants in its chemical structure. Furthermore, the term "two-chain type" refers to a type having eight or more carbon atoms, consisting of an alkyl or acyl group; additionally, the two chains may be identical or different from each other independently.

[0070] The bichain anionic surfactants of the present invention preferably have two alkyl or acyl groups having 8 to 20 carbon atoms, and more preferably have two alkyl groups having 12 to 18 carbon atoms. The bichain anionic surfactants of the present invention have carboxyl groups, thereby possessing anionic properties.

[0071] The bichain anionic surfactant of the present invention can be a bis(fatty acid amide glutamine) lysine salt. Examples of bis(fatty acid amide glutamine) lysine salts include, but are not limited to, bis(lauramide glutamine) lysine salts, bis(myristamide glutamine) lysine salts, bis(stearamide glutamine) lysine salts, and bis(linoleamide glutamine) lysine salts. Furthermore, examples of their salts include, for instance, alkali metal salts such as sodium and potassium salts, but are not limited to these.

[0072] More specifically, the bichain anionic surfactant involved in this invention is preferably sodium di(lauramide-glutamine)lysine.

[0073] Furthermore, the bichain anionic surfactants involved in this invention can be obtained by synthesis or by using commercially available products.

[0074] Commercially available products that are dichain anionic surfactants include, for example, Pelicair L-30 (sodium di(lauramide-glutamine)lysine) manufactured by Asahi Kasei Kemica Co., Ltd., but are not limited to these.

[0075] (Two-chain cationic surfactant)

[0076] In this invention, "cationic surfactant" may include agents or compounds that exhibit the properties of cationic surfactants in their chemical structure.

[0077] The bichain cationic surfactants involved in this invention preferably have two alkyl or acyl groups having 8 to 20 carbon atoms, and more preferably have two alkyl groups having 12 to 18 carbon atoms.

[0078] The bichain cationic surfactant involved in this invention can be a bichain cationic surfactant represented by the following general formula (I):

[0079]

[0080] In the formula, R1 and R2 each independently represent alkyl groups with 8 to 20 carbon atoms, R3 and R4 each independently represent alkyl groups, hydroxyl groups, or benzyl groups with 1 to 3 carbon atoms, and X represents a halogen atom.

[0081] In general formula (I), R1 and R2 each independently represent an alkyl group having 8 to 20 carbon atoms, preferably an alkyl group having 12 to 18 carbon atoms.

[0082] Furthermore, in general formula (I), R3 and R4 each independently represent an alkyl, hydroxyl, or benzyl group having 1 to 3 carbon atoms, preferably an alkyl group having 1 to 3 carbon atoms.

[0083] Furthermore, in general formula (I), X represents a halogen atom, preferably a Br atom or a Cl atom, and more preferably a Cl atom.

[0084] More specifically, the bichain cationic surfactant involved in this invention is preferably distearate dimethylammonium chloride.

[0085] Furthermore, the bichain cationic surfactants involved in this invention can be obtained by synthesis or by using commercially available products.

[0086] <Properties of Vesicle Compositions>

[0087] The vesicle composition of the present invention can be any of the following forms: transparent, translucent, and opaque. However, when used as a cosmetic base where transparency is required, it is preferably transparent or translucent. Here, "transparent or translucent" means that the L value in the cosmetic's Lab colorimetric system (Hunter Lab system) is 50 or higher. The L value represents the transparency when the transparency of purified water is set to 100 and the case of complete opacity is set to 0. That is, the closer the L value is to 100, the higher the transparency. Therefore, the vesicle composition of the present invention preferably has an L value of 50 or higher, and more specifically, preferably an L value of 50.0 or higher, 60.0 or higher, 70.0 or higher, 80.0 or higher, 90.0 or higher, 92.0 or higher, 94.0 or higher, 96.0 or higher, 98.0 or higher, or 100.0. In addition, the L value can be measured, for example, using a spectrophotometer SE7700 (manufactured by Nippon Denshoku Kogyo Co., Ltd.).

[0088] The pH value of the vesicle composition of the present invention is not particularly limited, but when used as a cosmetic base, it can be 6.80 or higher, 7.00 or higher, 7.10 or higher, 7.20 or higher, 7.30 or higher, 7.40 or higher, 7.50 or higher, 7.60 or higher, 7.70 or higher, 7.80 or higher, 7.85 or higher, 7.90 or higher, 7.91 or higher, 7.92 or higher, 7.93 or higher, 7.94 or higher, 7.95 or higher, 7.96 or higher, 7.97 or higher, 7.98 or higher, 7.99 or higher, 8.00 or higher, or 8.10 or higher, and can also be 8.50 or lower. Furthermore, the pH value is measured at a temperature of 30°C.

[0089] <Uses of the vesicle composition>

[0090] Since the vesicle composition of the present invention can encapsulate pharmaceutical agents in the hydrophobic and hydrophilic portions of the vesicles, it can be applied to cosmetic bases, pesticides, drug delivery, pharmaceuticals, inks, etc.

[0091] (Cosmetic base)

[0092] The vesicle composition of the present invention can be used as a cosmetic base for application to the skin, etc. Therefore, the present invention provides a cosmetic base comprising the vesicle composition of the present invention.

[0093] Examples of cosmetic ingredients include, for instance, skin care cosmetics such as lotions, moisturizing gels, massage gels, beauty serums, and lotions; makeup cosmetics; sunscreens; hair cosmetics such as hair styling products or hairsprays; and hair dyes. The vesicle composition of the present invention can be appropriately used depending on the form and properties of these cosmetic ingredients. For example, when the purpose is to create a semi-transparent or transparent lotion, it is preferable to use the vesicle composition of the present invention containing vesicles with an average particle size of 150 nm or less.

[0094] <water>

[0095] In the vesicle composition of the present invention, the water content is not particularly limited, but from the viewpoint of vesicle formation, it can be 70% by mass or more, or 75% by mass or more, relative to the whole composition, or 95% by mass or less, 90% by mass or less, or 80% by mass or less.

[0096] 〈Oily ingredients〉

[0097] In the vesicle composition of the present invention, an oily component can be retained within the vesicle, that is, within the bilayer of the vesicle. The oily component that can be retained in the vesicle is not limited to the following substances, but at least one selected from polar oils and silicone oils can be used. The oily component that can be retained in the vesicle can be appropriately selected based on the IOB value, etc. For example, in the case of using vesicles formed by organosilicon surfactants, from the viewpoint of vesicle stability, at least one selected from polar oils with an IOB value of 0.05 to 0.80 and silicone oils is preferred. Here, the IOB value of the oily component can be calculated based on its structure using known calculation methods.

[0098] The oily component relative to the vesicles can be maintained at 10% by mass or less, preferably at 10.0% by mass or less, 9.0% by mass or less, 8.0% by mass or less, 7.0% by mass or less, 6.0% by mass or less, 5.0% by mass or less, or 4.0% by mass or less. Furthermore, it can be maintained at 0.5% by mass or more, 1.0% by mass or more, 2.0% by mass or more, or 3.0% by mass or more. Additionally, the oily component relative to the total amount of the vesicle composition can be blended at 0.001% by mass or more, 0.005% by mass or more, 0.01% by mass or more, 0.05% by mass or more, or 0.1% by mass or more. Furthermore, it can be blended at 1.0% by mass or less, 0.5% by mass or less, or 0.3% by mass or less. The vesicle composition of the present invention can also be used with polar oils other than those with an IOB value of 0.05 to 0.80, or with non-polar oils such as mineral oil, without impairing the stability of the vesicles.

[0099] (Polar oil)

[0100] Examples of polar oils include isostearic acid, isopropyl myristate, cetyl octanoate, octyl dodecyl myristate, isopropyl palmitate, butyl stearate, hexyl laurate, myristyl myristate, decyl oleate, hexyl decyl dimethyl octanoate, isononyl isononanoate, cetyl lactate, myristyl lactate, acetylated lanolin, isocetyl stearate, isocetyl isostearate, cetyl ethylhexanoate, and cholesterol 12-hydroxystearate. 2-Ethylhexanoate, dipentaerythritol fatty acid ester, N-alkyl diol monoisostearate, neopentyl glycol didecanoate, diisostearate malate, di-2-heptylundecanoate glyceryl ester, trimethylolpropane tri-2-ethylhexanoate, trimethylolpropane triisostearate, pentaerythritol tetra-2-ethylhexanoate, tri-2-ethylhexanoate glyceryl ester (triisooctanoate), trimethylolpropane triisostearate, cetyl isooctanoate, cetyl 2-ethylhexanoate, 2 -Ethylhexyl palmitate, alkyl benzoate (carbon number 12-15), cetearyl isononanoate, tri(caprylic / capric) glyceryl ester, (dicaprylic / capric) butylene glycol ester, trimyristic acid glyceryl ester, tri-2-heptylundecanoic acid glyceryl ester, castor oil fatty acid methyl ester, oleic acid oleate, cetyl alcohol and stearyl alcohol mixture, acetylglycine ester, 2-heptylundecyl palmitate, diisobutyl adipate, N-lauroyl-L-glutamic acid-2-octyldodecyl Esters, di-2-heptylundecyl adipate, ethyl laurate, di-2-ethylhexyl sebacate, 2-hexyldecyl myristate, 2-hexyldecyl palmitate, 2-hexyldecyl adipate, diisopropyl sebacate, di-2-ethylhexyl succinate, ethyl acetate, butyl acetate, amyl acetate, triethyl citrate, 2-ethylhexyl p-methoxycinnamate, tripropylene glycol dinepentanoate, 2-ethylhexyl 2-cyano-3,3-diphenylacrylate, etc. Polar oils can be selected in combination with one or more of these.

[0101] (Silicone oil)

[0102] Silicone oils are not particularly limited as long as they are oily components with a polysiloxane structure; they can use either linear or cyclic structures, or be volatile or non-volatile. Examples of silicone oils include chain silicones such as dimethylpolysiloxane, methylphenylpolysiloxane, and methyl hydrogen-containing polysiloxane, as well as cyclic silicones such as octamethylcyclotetrasiloxane, decamethylcyclopentasiloxane, and dodecylcyclohexasiloxane. One or more of these can be selected and used in combination.

[0103] Among these silicone oils, volatile cyclic silicone oils, particularly octamethylcyclotetrasiloxane and decamethylcyclopentasiloxane, are suitable. By using such volatile cyclic silicone oils, not only can more fragrance components be introduced into the vesicle bilayer, but the vesicle composition also exhibits less stickiness when used as a topical agent, resulting in an excellent user experience. As non-volatile silicone oils, diphenylsiloxyphenyl polytrimethylsiloxane and methylphenyl polysiloxane are particularly preferred.

[0104] <Other Ingredients>

[0105] The vesicle composition of the present invention can be appropriately blended with various components, depending on the intended use of the composition, without affecting the formation and stability of the vesicles. Examples of these components include additives commonly blendable in cosmetics, such as lower alcohols, polyols, various extracts, moisturizers, antioxidants, buffers, preservatives, pigments, fragrances, chelating agents, pH adjusters, and UV absorbers. Depending on their properties, these components can be blended into an aqueous phase as the continuous phase in the vesicle composition, an aqueous phase as the dispersed phase within the vesicles, or an oil phase as the dispersed phase within the vesicle bilayer.

[0106] In the aqueous phase, in addition to water-soluble agents applicable to pharmaceuticals, quasi-pharmaceuticals, cosmetics, etc., any aqueous component used in pharmaceuticals or cosmetics can generally be mixed in a mixing amount that does not affect the stability of the vesicles. In particular, from the viewpoint of vesicle stabilization or user experience, it is preferable to mix one or more aqueous components selected from ethanol and polyols.

[0107] Examples of polyols include ethylene glycol, propylene glycol, 1,3-butanediol, 1,4-butanediol, glycerol, sorbitol, diethylene glycol, dipropylene glycol, 1,4-butanediol, diglycerol, polyethylene glycol, and polypropylene glycol, with propylene glycol, dipropylene glycol, and 1,3-butanediol being particularly preferred. One or more aqueous components selected from ethanol and polyols can be mixed in a range of 1 to 20% by mass or 3 to 10% by mass relative to the total amount of the composition.

[0108] Method for manufacturing vesicle compositions

[0109] Furthermore, the present invention provides a method for manufacturing a vesicle composition. The vesicle composition of the present invention can be manufactured by either method 1 or method 2.

[0110] <Method 1>

[0111] The method for manufacturing the vesicle composition of the present invention comprises:

[0112] An alcohol solution containing a bichain anionic surfactant and a bichain cationic surfactant is mixed with water to form vesicles.

[0113] Here, the bichain anionic surfactant and the bichain cationic surfactant can be dissolved together in the alcohol solution, or they can be dissolved separately in the alcohol solution and then mixed. Additionally, in this invention, the mixing process may include appropriate stirring.

[0114] Furthermore, the dissolution of bichain anionic surfactants and bichain cationic surfactants in alcohol solutions can be carried out at room temperature or with moderate heating.

[0115] There are no particular limitations on the alcohol used; for example, it can be a monohydric alcohol such as methanol or ethanol, or a dihydric alcohol such as dipropylene glycol.

[0116] When an alcohol solution containing a bichain anionic surfactant and a bichain cationic surfactant is mixed with water, the alcohol solution containing the bichain anionic surfactant and a bichain cationic surfactant can be added to the water, or water can be added to the alcohol solution containing the bichain anionic surfactant and a bichain cationic surfactant, but the former is preferred.

[0117] Furthermore, when mixing with other components, they can be mixed in water or in an alcohol solution containing a dichain anionic surfactant and a dichain cationic surfactant, depending on the properties of the components being mixed. For example, when mixing an oily component into vesicles, it is preferable to mix such an oily component in an alcohol solution containing a dichain anionic surfactant and a dichain cationic surfactant.

[0118] In this manufacturing method, vesicles composed of the two-chain anionic and cationic surfactants are spontaneously formed in an aqueous phase by mixing an alcohol solution containing both anionic and cationic surfactants with water. When an oily component is included along with the two-chain anionic and cationic surfactants, this oily component is introduced by solubilization within the bilayer membrane of the formed vesicles.

[0119] <Method 2>

[0120] The method for manufacturing the vesicle composition of the present invention comprises:

[0121] This allows bichain anionic and bichain cationic surfactants to dissolve in water, forming vesicles.

[0122] Here, the bichain anionic surfactant and the bichain cationic surfactant can be dissolved together in water, or they can be dissolved separately in water and then mixed.

[0123] Furthermore, the dissolution of bichain anionic surfactants and bichain cationic surfactants in water can be carried out at room temperature or with moderate heating.

[0124] In this manufacturing method, vesicles formed by the two-chain anionic surfactant and the two-chain cationic surfactant are spontaneously formed in the aqueous phase by mixing an alcohol solution containing dissolved bichain anionic surfactant and bichain cationic surfactant with water.

[0125] Example

[0126] The following examples illustrate the invention in further detail, but the invention is not limited thereto. Furthermore, unless otherwise specified, the mixing amount is expressed as a percentage by mass.

[0127] Example 1

[0128] In Example 1, vesicle formation at a molar ratio of sodium bis(lauramide-glutamine)lysine to distearate dimethylammonium chloride of 6:4 was confirmed by 30,000x magnification observation using a Cryo-TEM (JEM-2200FS, camera DE-20, manufactured by JEOL). The observation temperature was low (-175±1.7℃). The results are shown in... Figure 2 middle.

[0129] In addition, the components mixed in the vesicle composition of Example 1 are as follows:

[0130]

[0131] Depend on Figure 2 It is clear that in Example 1, vesicles with a cross-section resembling that of an onion were formed.

[0132] Examples 2-4 and Comparative Examples 1-3

[0133] Based on the formulations shown in Table 1 below and the manufacturing methods described below, composition samples of Examples 2-4 and Comparative Examples 1-3 were manufactured.

[0134] <Manufacturing methods of Examples 2-4>

[0135] Based on steps 1 to 5 below, the compositions of Examples 2 to 4 are prepared:

[0136] 1. Mix (1) to (7) shown in Table 1 at room temperature until they dissolve.

[0137] 2. Heat and mix (10) and (9) shown in Table 1, dissolve them at 80°C, and then cool them down to 40°C.

[0138] 3. Mix (11) to (14) shown in Table 1 at room temperature until they dissolve.

[0139] 4. The substances obtained in steps 2 and 3 above were stirred and mixed.

[0140] 5. The substances obtained in steps 1 and 4 above were stirred and mixed.

[0141] <Manufacturing methods of Comparative Examples 1-3>

[0142] Based on steps 1 to 5 below, compositions of Comparative Examples 1 to 3 were prepared:

[0143] 1. Mix (1) to (7) shown in Table 1 at room temperature until they dissolve.

[0144] 2. Heat and mix (8) and (9) shown in Table 1, dissolve them at 80°C, and then cool them down to 40°C.

[0145] 3. Mix (11) to (14) shown in Table 1 at room temperature until they dissolve.

[0146] 4. The substances obtained in steps 2 and 3 above were stirred and mixed.

[0147] 5. The substances obtained in steps 1 and 4 above were stirred and mixed.

[0148] <evaluate>

[0149] (Determination of average particle size)

[0150] The average particle size of vesicles or vesicle-like substances in the compositions obtained in each example and comparative example was determined using dynamic light scattering with a Zetasizer Nano ZS (manufactured by Sysmex). The results are shown in Table 1.

[0151] (Determination of L value)

[0152] The L values ​​of the compositions obtained in each example and comparative example were determined using a spectrophotometer SE7700 (manufactured by Nippon Denshoku Kogyo Co., Ltd.). The respective results are shown in Table 1.

[0153] (pH measurement)

[0154] The pH values ​​of the compositions obtained in each example and comparative example were measured using a pH meter F-52 (manufactured by Horiba Manufacturing Co., Ltd.). The respective results are shown in Table 1.

[0155] The L values ​​of the compositions obtained in each example and comparative example were determined using a spectrophotometer SE7700 (manufactured by Nippon Denshoku Kogyo Co., Ltd.) after storage at temperatures of 0°C, 25°C, 37°C, and 50°C for one month. The results are shown in Table 1.

[0156] [Table 1] Table 1

[0157]

[0158] As shown in Table 1, vesicles can be formed in Examples 2 to 4. The L value after one month of storage is the same as before storage, indicating excellent storage stability.

[0159] In contrast, the material obtained in Comparative Example 1 had an average particle size of 8.2 nm, suggesting that it was not a vesicle but a micelle.

[0160] Furthermore, the substance obtained in Comparative Example 2 was presumed to be an emulsion or suspension rather than a vesicle, as it had an average particle size of 249.1 nm, a low L value, and low transparency (close to opaque).

[0161] Furthermore, the average particle size of the substance obtained in Comparative Example 3 was 8.2 nm, suggesting that it was not a vesicle but a micelle. That is, Comparative Example 3, which used a single-chain cationic surfactant, could not form vesicles.

[0162] Examples of Prescriptions for Vesicle Compositions

[0163] The following are examples of cosmetic formulations using the vesicle composition of the present invention as a base, but are not limited to these examples.

[0164] <Prescription Example 1: Clear Whitening Toner>

[0165]

[0166] The resulting whitening toner had emulsified particles of 71 nm, a pH of 8.13, and an L value of 97.

[0167] <Prescription Example 2: Thick Toner>

[0168]

[0169] The resulting viscous toner had a viscosity of 85 mPa·s and a pH of 7.84.

[0170] In addition, the viscosity was evaluated using a type B viscometer (TVB-10 viscometer, manufactured by Toki Sangyo Co., Ltd.) under the conditions of rotor number M2, 30°C, and 12 rpm.

Claims

1. A vesicle composition comprising: Water; and Vesicles made from bichain anionic surfactants and bichain cationic surfactants. The bichain anionic surfactant is sodium bis(lauramide-glutamine)lysine. The two-chain cationic surfactant is distearate dimethylammonium chloride. The molar ratio of the bichain anionic surfactant to the bichain cationic surfactant is 7:3 to 5:

5.

2. The vesicle composition according to claim 1, wherein the average particle size of the vesicles is less than 150 nm.

3. The vesicle composition according to claim 1 or 2, wherein the vesicles retain an oily component.

4. A cosmetic base comprising the vesicle composition according to any one of claims 1 to 3.

5. A method for manufacturing the vesicle composition according to any one of claims 1 to 3, comprising: mixing an alcohol solution in which the bichain anionic surfactant and the bichain cationic surfactant are dissolved with water to form the vesicles.

6. A method for manufacturing the vesicle composition according to any one of claims 1 to 3, comprising: dissolving the bichain anionic surfactant and the bichain cationic surfactant in water to form the vesicles.

Images